On the public citation graph

Dysbiosis of Fecal Microbiota in Chinese Advanced Non-Small-Cell Lung Cancer Patients and its Role in Response to Immunotherapy

https://doi.org/10.2139/ssrn.4792764
0 signed · 30 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/ijc.32003openalex-extracted
Fecal microbiota transplantation in cancer management: Current status and perspectives
inferredcites →https://doi.org/10.1007/s00432-021-03644-0openalex-extracted
Role of lung and gut microbiota on lung cancer pathogenesis
inferredcites →https://doi.org/10.1007/s10482-020-01474-7openalex-extracted
Human gut microbiota/microbiome in health and diseases: a review
inferredcites →https://doi.org/10.1007/s11274-021-03086-3openalex-extracted
Association of gut microbiomes with lung and esophageal cancer: a pilot study
inferredcites →https://doi.org/10.1016/j.ccell.2015.11.010openalex-extracted
Immunotherapy Not Working? Check Your Microbiota
inferredcites →https://doi.org/10.1016/j.chom.2016.07.001openalex-extracted
Gut Microbial Metabolites Fuel Host Antibody Responses
inferredcites →https://doi.org/10.1016/j.critrevonc.2019.102841openalex-extracted
Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer—A review
inferredcites →https://doi.org/10.1016/j.jtho.2019.04.007openalex-extracted
The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC
inferredcites →https://doi.org/10.1016/j.jtho.2020.04.028openalex-extracted
Lung Cancer in People’s Republic of China
inferredcites →https://doi.org/10.1016/j.pharmthera.2021.107973openalex-extracted
The gut microbiome and efficacy of cancer immunotherapy
inferredcites →https://doi.org/10.1016/j.psychres.2019.112691openalex-extracted
A review of antibiotics, depression, and the gut microbiome
inferredcites →https://doi.org/10.1038/s41467-021-23265-yopenalex-extracted
Identification of microbial markers across populations in early detection of colorectal cancer
inferredcites →https://doi.org/10.1038/s41575-020-00376-3openalex-extracted
Utilizing the gut microbiome in decompensated cirrhosis and acute-on-chronic liver failure
inferredcites →https://doi.org/10.1038/s41591-021-01655-5openalex-extracted
Intestinal Akkermansia muciniphila predicts clinical response to PD-1 blockade in patients with advanced non-small-cell lung cancer
inferredcites →https://doi.org/10.1038/s41598-020-65792-6openalex-extracted
Impact of pemetrexed chemotherapy on the gut microbiota and intestinal inflammation of patient-lung-derived tumor xenograft (PDX) mouse models
inferredcites →https://doi.org/10.1053/j.gastro.2018.04.001openalex-extracted
Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response
inferredcites →https://doi.org/10.1080/1040841x.2016.1176988openalex-extracted
Gut–lung axis: The microbial contributions and clinical implications
inferredcites →https://doi.org/10.1111/1759-7714.14199openalex-extracted
Intestinal flora characteristics of advanced non‐small cell lung cancer in China and their role in chemotherapy based on metagenomics: A prospective exploratory cohort study
inferredcites →https://doi.org/10.1126/science.aac4255openalex-extracted
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
inferredcites →https://doi.org/10.1126/science.aad1329openalex-extracted
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
inferredcites →https://doi.org/10.1126/science.aan3706openalex-extracted
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
inferredcites →https://doi.org/10.1126/science.abb5920openalex-extracted
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patients
inferredcites →https://doi.org/10.1126/science.abf3363openalex-extracted
Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
inferredcites →https://doi.org/10.1667/rr15579.1openalex-extracted
The Intestinal Microbiota Plays as a Protective Regulator Against Radiation Pneumonitis
inferredcites →https://doi.org/10.21037/tlcr.2019.10.23openalex-extracted
The role of the gut microbiome on the efficacy of immune checkpoint inhibitors in Japanese responder patients with advanced non-small cell lung cancer
inferredcites →https://doi.org/10.2217/fon-2019-0783openalex-extracted
Gut microbiota and cancer immunotherapy: prognostic and therapeutic implications
inferredcites →https://doi.org/10.3389/fcimb.2019.00112openalex-extracted
Dysbiosis of the Gut Microbiome in Lung Cancer
inferredcites →https://doi.org/10.3389/fcimb.2021.725284openalex-extracted
Specific Gut Microbiome and Serum Metabolome Changes in Lung Cancer Patients
inferredcites →https://doi.org/10.3390/cancers13194824openalex-extracted
The Gut Microbiome and Cancer Immunotherapy: Can We Use the Gut Microbiome as a Predictive Biomarker for Clinical Response in Cancer Immunotherapy?
inferredcites →https://doi.org/10.7150/ijbs.35980openalex-extracted
Dysbiosis of the Gut Microbiome is associated with Tumor Biomarkers in Lung Cancer
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.